Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins„¢ as a new class of potent and selective medicines to treat a wide range of cancers, today announced that the company will present at the European CanCer Organisation (ECCO) EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium occurring November 13-16, 2018 in Dublin, Ireland.
Samantha Perino, from Tarveda, will present at the Molecular Targeted Agents – PART II poster session from 10:00-2:00 PM GMT on Friday, November 16. The poster is entitled, Leveraging the Pentarin Platform to Selectively Deliver PI3K Inhibitors to Solid Tumors Leading to Superior Efficacy in Preclinical Models.
Our presentation at the Molecular Targets and Cancer Therapeutics Symposium will detail how we are leveraging our HSP90 binding conjugate platform to mask the activity of the conjugated payloads in the circulation while accumulating HSP90 binding conjugates in the tumors. The resulting sustained release of active anti-cancer payloads in the tumor, such as phosphoinositide 3-kinase (PI3K) inhibitors, then drives the efficacy, said Richard Wooster, Ph.D., President of Research and Development and Chief Scientific Officer at Tarveda. The power of targeting potent therapies to tumors is exemplified by our first HSP90 binding conjugate, PEN-866, which carries the topoisomerase I inhibitor SN-38 as its payload. PEN-866 is currently in a Phase 1/2a trial to assess safety and efficacy across a range of tumor types. The data with a PI3K inhibitor in our presentation demonstrates the potential to significantly enhance kinase inhibitor performance using our HSP90 binding conjugate platform.
Tarveda is developing Pentarins, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarvedas Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligands targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell killing payload inside the cancer cells for efficacy.
About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc. discovers and develops Pentarins, a new class of potent and selective miniature drug conjugates with enhanced targeting capabilities for the treatment of a wide range of solid tumor cancers. Tarvedas lead Pentarin drug candidate, PEN-221, is a miniature drug conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment of patients with neuroendocrine, small cell lung, prostate, and other cancers that express SSTR2. PEN-221 comprises a highly selective peptide for SSTR2 conjugated to the potent cytotoxic payload, DM1, through a tuned cleavable linker. Tarveda is also advancing its Pentarin HSP90 drug conjugate platform with lead drug candidate PEN-866, which is a miniature drug conjugate that selectively binds to the intracellular target, Heat Shock Protein 90 (HSP90) and is linked to the payload SN-38, a potent topoisomerase I inhibitor. Tarvedas strategy includes developing its own proprietary Pentarins as well as applying the Pentarin platform to enhance the effectiveness of the targeting moieties and novel payloads of pharmaceutical collaborators. http://www.tarvedatx.com/
MacDougall Biomedical Communications
Amanda Houlihan, 781-235-3060